Table 1 Baseline characteristics
From: Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study
Acetylsalicylic acid | Acetylsalicylic acid + dipyridamole | Clopidogrel | p-value | |
|---|---|---|---|---|
(n = 3043) | (n = 12,295) | (n = 3885) | ||
Age in years, median (IQR) | 75.3 (64.4–83.7) | 70.7 (61.5–79.6) | 68.6 (59.2–77.6) | >0.0001 |
Men (%) | 47.5 % | 56.5 % | 49.3 % | >0.0001 |
Diabetes | 380 (12.5 %) | 1449 (11.8 %) | 455 (11.7 %) | 0.5263 |
Hypertension | 1316 (43.2 %) | 4987 (40.6 %) | 1644 (42.3 %) | 0.0102 |
Myocardial infarction | 334 (11 %) | 824 (6.7 %) | 523 (13.5 %) | <0.01 |
Peripheral artery disease | 126 (4.1 %) | 297 (2.4 %) | 180 (4.6 %) | <0.01 |
Heart failure | 222 (7.3 %) | 496 (4 %) | 229 (5.9 %) | <0.01 |
Cancer | 206 (6.8 %) | 714 (5.8 %) | 245 (6.3 %) | 0.1062 |
Chronic obstructive pulmonary disease | 256 (8.4 %) | 808 (6.6 %) | 274 (7.1 %) | <0.01 |
Previous bleeding | 405 (13.3 %) | 853 (6.9 %) | 319 (8.2 %) | <0.01 |
NSAIDS | 485 (15.9 %) | 1751 (14.2 %) | 600 (15.4 %) | 0.0243 |